An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC)
Publication
, Conference
Bardia, A; O'Sullivan, CC; Mahtani, RL; Blau, S; Abdulla, NE; Ali, A; Bansal, R; Meyer, JM; George, MA; Han, HS; Pluard, TJ; Papish, SW ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Bardia, A., O’Sullivan, C. C., Mahtani, R. L., Blau, S., Abdulla, N. E., Ali, A., … Rugo, H. S. (2024). An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Bardia, Aditya, Ciara Catherine O’Sullivan, Reshma L. Mahtani, Sibel Blau, Nihal E. Abdulla, Azka Ali, Rani Bansal, et al. “An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Bardia A, O’Sullivan CC, Mahtani RL, Blau S, Abdulla NE, Ali A, et al. An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC). In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Bardia, Aditya, et al. “An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.
Bardia A, O’Sullivan CC, Mahtani RL, Blau S, Abdulla NE, Ali A, Bansal R, Meyer JM, George MA, Han HS, Pluard TJ, Papish SW, Jones JM, Rong Y, Gao G, Rugo HS. An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC). JOURNAL OF CLINICAL ONCOLOGY. 2024.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences